Insight Molecular Diagnostics Inc. (formerly OncoCyte Corporation) Overview
Pro stress-test →OncoCyte is a precision diagnostics and monitoring company focused on improving cancer patient outcomes through advanced testing solutions. The company is capturing value in the estimated $1 billion total addressable market for transplant rejection testing, while maintaining a clinical oncology portfolio.
Strategic Profile
Pro stress-test →The company is rebranding itself to better align with its broader market focus on both transplant and oncology diagnostics. OncoCyte has completed the design of its clinical molecular diagnostic testing kit and secured approval from a major institutional review board, with plans to involve three of the top ten U.S. transplant centers in an upcoming clinical trial.
Competitive Landscape
Pro stress-test →OncoCyte competes in the precision diagnostics space against companies like Guardant Health, Guardant Health, Zymo Research, and others focused on liquid biopsy and transplant monitoring. Its differentiation lies in transplant rejection testing with a defined $1B TAM and partnerships with major transplant centers, though it remains an earlier-stage entrant compared to established cancer diagnostic players.
Industry Context
Insight Molecular Diagnostics Inc. (formerly OncoCyte Corporation) operates in Precision Diagnostics / Medical Device Testing (Cancer & Transplant Rejection Monitoring).
Key facts
Founded: 2009 · Headquarters: Nashville, Tennessee · Employees: N/A · Revenue: $2.1M (Q1 2025) · Market cap: N/A